Physician profile
Joykumar G Patel
NPI 1730310210
$507,756.42
in general payments reported to CMS, 2019-2025
16 companies · $152K in 2025
The $152K reported for 2025 was more than what 96% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $23K · 2021: $34K · 2022: $46K · 2023: $64K · 2024: $152K · 2025: $152K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $56K · Travel and Lodging: $34K · Food and Beverage: $12K · Consulting Fee: $8,460 · Honoraria: $6,624 · Education: $72.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $249,994.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $55,660.00 |
| Travel and Lodging | $33,842.33 |
| Food and Beverage | $12,244.67 |
| Consulting Fee | $8,460.00 |
| Honoraria | $6,624.00 |
| Education | $72.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $141,037.95 | 2019-2025 | Epclusa, Livdelzi, Vemlidy |
| Intercept Pharmaceuticals, INC. | $110,611.46 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $88,209.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $72,712.06 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $66,365.01 | 2024-2025 | Iqirvo, Bylvay |
| Novo Nordisk INC | $14,413.79 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $13,237.01 | 2022-2025 | Terlivaz |
| Eisai INC. | $787.50 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.57 | 2019-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $30.13 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.97 | 2019 | |
| Eurofins Viracor, LLC | $15.06 | 2024 | |
| Sobi, INC | $13.05 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joykumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.